Xiaoyuan Tian

Xiaoyuan Tian

Auto-generated profile, based on publicly available information

Xiaoyuan Tian

Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
XTXiaoyuan Tian
Xiaoyuan Tian
ZQZhenan Qu
Zhenan Qu
YCYing Cao
Ying Cao
BZBo'cheng Zhang
Bo'cheng Zhang
Introduction: The aim of this meta-analysis was to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of knee osteoarthritis (OA). Methods: The PubMed, Embase, Cochrane Central Register of Controlled Trials, Scopus and Web of Science databases were searched from inception to May 6, 2024 to identify randomized controlled trials that compared MSCs and placebo or other nonsurgical approaches for treating OA. Two investigators independently searched the literature and extracted data, and conventional meta-analyses were conducted with Review Manager 5.3. The outcomes included pain relief, functional improvement, and risk of adverse events (AEs).Results: A total of 18 articles were included. Overall, MSCs were superior to placebo in terms of relieving pain and improving function at the 12-month follow-up. However, the differences in treatment-related AEs were not significant.Conclusion: MSCs may relieving pain and improving function of OA. The limitations of this study include the high heterogeneity of the included studies. Additionally, the follow-up time in the included studies was relatively short, so more clinical trials are needed to predict the long-term efficacy and safety of MSCs.Systematic review registration: https://doi.org/10.17605/OSF.IO/5BT6E, identifier CRD42022354824.

28 May 2021 in Nanomedicine
Verified
Journal Article
Closed access
BZBo'cheng Zhang
Bo'cheng Zhang
XTXiaoyuan Tian
Xiaoyuan Tian
ZQZhenan Qu
Zhenan Qu
JLJiaming Liu
Jiaming Liu
LYLiang Yang
Liang Yang
WZweiguo zhang
weiguo zhang
Background: Some studies have reported results from the use of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) to treat osteoarthritis (OA). Objective: To evaluate the efficacy of MS...

1 January 2025 in International Journal of Genomics
Verified
Journal Article
Open access
TLTaiyao Li
Taiyao Li
YCYing Cao
Ying Cao
JWJie Wang
Jie Wang
XTXiaoyuan Tian
Xiaoyuan Tian
BDBin Dong
Bin Dong
YYYanqin Yang
Yanqin Yang
Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis‐related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival outcomes. Functional enrichment and immune‐related analyses revealed that the high‐risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune‐related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high‐risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.